Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer ...Middle East

SAN FRANCISCO and SUZHOU,China, April 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and...

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer )

Also on site :

• Hezbollah leader says Lebanese gov’t must do more to end Israeli attacks
• Congress returns as Trump’s domestic agenda hangs by a thread
• Reeves warned employment rights law has already led to hiring freeze and loss of business confidence